Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV trial of 23-valent pneumococcal polysaccharide vaccine
ChiCTR2200056827Phase 4Not yet recruiting
- Sponsor
- Hubei Provincial Center for Disease Control and Prevention
- Start
- Feb 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Hubei Provincial Center for Disease Control and Prevention. Primary endpoints: Adverse reactions and adverse events, Positive conversion rate of pneumococcal IgG antibody of each serotype and 3 more. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on ChiCTR2200056827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056827.